<?xml version='1.0' encoding='utf-8'?>
<document id="26341013"><sentence text="Drug-drug interactions between clopidogrel and novel cardiovascular drugs."><entity charOffset="31-42" id="DDI-PubMed.26341013.s1.e0" text="clopidogrel" /></sentence><sentence text="The combination of aspirin and the thienopyridine clopidogrel is a cornerstone in the prevention of atherothrombotic events"><entity charOffset="19-26" id="DDI-PubMed.26341013.s2.e0" text="aspirin" /><entity charOffset="35-61" id="DDI-PubMed.26341013.s2.e1" text="thienopyridine clopidogrel" /><pair ddi="false" e1="DDI-PubMed.26341013.s2.e0" e2="DDI-PubMed.26341013.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26341013.s2.e0" e2="DDI-PubMed.26341013.s2.e1" /></sentence><sentence text=" These two agents act in concert to ameliorate the prothrombotic processes stimulated by plaque rupture and vessel injury complicating cardiovascular disease" /><sentence text=" Guidelines recommend the use of clopidogrel in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention, and the drug remains the most utilized P2Y12 receptor inhibitor despite the fact that newer antiplatelet agents are now available"><entity charOffset="33-44" id="DDI-PubMed.26341013.s4.e0" text="clopidogrel" /></sentence><sentence text=" In recent years, numerous studies have shown inconsistency in the efficacy of clopidogrel to prevent atherothrombotic events"><entity charOffset="79-90" id="DDI-PubMed.26341013.s5.e0" text="clopidogrel" /></sentence><sentence text=" Studies of platelet function testing have shown variability in the response to clopidogrel"><entity charOffset="80-91" id="DDI-PubMed.26341013.s6.e0" text="clopidogrel" /></sentence><sentence text=" One of the major reason for this phenomenon lies in the interaction between clopidogrel and other drugs that may affect clopidogrel absorption, metabolism, and ultimately its antiplatelet action"><entity charOffset="77-88" id="DDI-PubMed.26341013.s7.e0" text="clopidogrel" /><entity charOffset="121-132" id="DDI-PubMed.26341013.s7.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.26341013.s7.e0" e2="DDI-PubMed.26341013.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26341013.s7.e0" e2="DDI-PubMed.26341013.s7.e1" /></sentence><sentence text=" Importantly, these drug-drug interactions have prognostic implications, since patients with high on-treatment platelet reactivity associated with reduced clopidogrel metabolism have an increased risk of ischemia"><entity charOffset="155-166" id="DDI-PubMed.26341013.s8.e0" text="clopidogrel" /></sentence><sentence text=" Previous systematic reviews have focused on drug-drug interactions between clopidogrel and specific pharmacologic classes, such as proton pump inhibitors, calcium channel blockers, and statins"><entity charOffset="76-87" id="DDI-PubMed.26341013.s9.e0" text="clopidogrel" /><entity charOffset="156-163" id="DDI-PubMed.26341013.s9.e1" text="calcium" /><pair ddi="false" e1="DDI-PubMed.26341013.s9.e0" e2="DDI-PubMed.26341013.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26341013.s9.e0" e2="DDI-PubMed.26341013.s9.e1" /></sentence><sentence text=" However, more recent pieces of scientific evidence show that clopidogrel may also interact with newer drugs that are now available for the treatment of cardiovascular patients"><entity charOffset="62-73" id="DDI-PubMed.26341013.s10.e0" text="clopidogrel" /></sentence><sentence text=" Accordingly, the aim of this review is to highlight and discuss recent data on drug-drug interactions between clopidogrel and third-generation proton pump inhibitors, pantoprazole and lansoprazole, statins, pitavastatin, and antianginal drug, ranolazine"><entity charOffset="111-122" id="DDI-PubMed.26341013.s11.e0" text="clopidogrel" /><entity charOffset="168-180" id="DDI-PubMed.26341013.s11.e1" text="pantoprazole" /><entity charOffset="185-197" id="DDI-PubMed.26341013.s11.e2" text="lansoprazole" /><entity charOffset="208-220" id="DDI-PubMed.26341013.s11.e3" text="pitavastatin" /><entity charOffset="244-254" id="DDI-PubMed.26341013.s11.e4" text="ranolazine" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e0" e2="DDI-PubMed.26341013.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e0" e2="DDI-PubMed.26341013.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e0" e2="DDI-PubMed.26341013.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e0" e2="DDI-PubMed.26341013.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e0" e2="DDI-PubMed.26341013.s11.e4" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e1" e2="DDI-PubMed.26341013.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e1" e2="DDI-PubMed.26341013.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e1" e2="DDI-PubMed.26341013.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e1" e2="DDI-PubMed.26341013.s11.e4" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e2" e2="DDI-PubMed.26341013.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e2" e2="DDI-PubMed.26341013.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e2" e2="DDI-PubMed.26341013.s11.e4" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e3" e2="DDI-PubMed.26341013.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26341013.s11.e3" e2="DDI-PubMed.26341013.s11.e4" /></sentence><sentence text=" " /></document>